News

Latest news

Hide mandatory notifications of trade

Minutes from the Annual General Meeting of Nutri Pharma ASA

19.05.2010 - Nutri Pharma ASA´s Annual General Meeting was held today, 19 May 2010. All proposed resolutions in the notice to the meeting were approved by the shareholders

Nutri Pharma ASA´s Annual General Meeting was held today, 19 May 2010.  All
proposed resolutions in the notice to the meeting were approved by the
shareholders.

Important resolutions include:

  * Item 6: Proposed amendments to the articles of association:

a.       Name and Organization
b.      Intent and Purpose
c.       Nomination committee

The AGM resolved to change the name of the Company to Bionor Pharma ASA. The
Company will, in a separate release, communicate when the change will take
effect.

  * Item 7: Election of Board, chairman, and nomination committee

The AGM resolved to elect the following Board of Directors. The Board of
Directors will assume their responsibilities May 20, 2010:

Chairman of the Board:

  * §  Wenche Rolfsen (born 1952 ) has held several top positions within the
    pharmaceutical Industry, Pharmacia Corporation and has until recently held
    the managing Director role of Quintiles Scandinavia and Vice President of
    Quintiles Europe. Board member of Aker Biomarine ASA(listed on Oslo Børs)
    Aprea AB(Chairman), Denator AB(Chairman), Artimplant AB (listed on OMX
    Stockholm), Biovitrum  AB(listed on OMX Stockholm), Axis Shield (listed in
    London and Oslo Børs) and Industrifonden, Sweden.

Vice-Chairman of the Board:

  * Henrik Lund is Global Vice President MC Clinical Development, AstraZeneca
    R&D. Lund joined AstraZeneca in 1994 and since 2005 he has headed
    AstraZeneca's clinical development, phase I-III, across 43 subsidiaries.

Board Members:

  * Elsebeth Budolfsen (born 1947) has served as member of a number of Board of
    Directors in Europe and the US. Budolfsen served as CEO of ALK-Abello AS
    from 1979-2000 taking the company to a position of global leadership within
    the field of allergy vaccines.
  * Thomas Falck (born 1966) has served as Vice-Chairman of Biotec Pharmacon ASA
    (listed on Oslo Børs), and as board member or chairman of more than 45
    companies. Falck has served as the Chairman of NVCA - the Norwegian Venture
    Capital and Private Equity Association and as a board member of EVCA - the
    European Venture Capital and Private Equity Association.
  * Eric Cameron (born 1948) has 20 years of experience from the press and 10
    years comprehensive international business experience as executive director
    of Nycomed.

Nomination Committee:

  * Lars H. Høie
  * Ivar Sigurd Eide
  * Lars Helmer Enger

 

  * Item 10 : Authorization to increase the Company's share capital for use in
    the Company's long term incentive plan

The AGM resolved to grant the Board of Directors an authorization to increase
the Company's share capital by a maximum of 3 million shares. The authorization
will expire at the Company's next AGM

  * Item 11:  Authorization to increase the Company's share capital by 10 % for
    additional financing of R&D activities in Bionor Immuno AS

The AGM resolved to grant the Board of Directors an authorization to increase
the Company's share capital by a maximum of 18 million shares. The authorization
will expire at the Company's next AGM

 

See attachment for the complete Minutes of the Annual General Meeting

 

Contact information:
Trond Syvertsen
CEO, Nutri Pharma ASA
+47 917 21 457
+47 23 01 09 60

syvertsen@nutripharma.com <mailto:syvertsen@nutripharma.com>

 

 

This information is subject of the disclosure requirements acc. to §5-12 vphl
(Norwegian Securities Trading Act)


[HUG#1417257]